2
5
2
↑2
↓5
—2
Evidence suggests Psilocybin maydecreasePain.
5 studies (9 claims)
Emerging evidence
Typical effective dose 25 (25–25) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| methylphenidate or novel agents, such as ketamine or psilocybin | No effect - Existing evidence is inadequate to definitively recommend | cancer-related depression and pain | Human | patients with cancer pain and significant depression | Not specified | Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.cited 15× |
| Psilocybin-assisted therapy (PAT) | Decreases - clinically meaningful improvements | pain interference | Human | participants | Two oral doses (15 mg and 25 mg) administered two weeks apart. | Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. |
| Psilocybin-assisted therapy (PAT) | Decreases - clinically meaningful improvements | pain severity | Human | participants | Two oral doses (15 mg and 25 mg) administered two weeks apart. | Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. |
| psilocybin | Increases - motivated participation | benefits to personal pain management | Human | patients with chronic neuropathic pain | Not mentioned | Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.cited 1× |
| psilocybin | No effect - may represent barriers to conducting a randomized controlled trial | chronic neuropathic pain | Human | patients with chronic neuropathic pain | Not mentioned | Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial.cited 1× |
| psilocybin | Decreases - anti-nociceptive treatments | chronic pain | Human | preclinical animal models | Not specified | Psilocybin as a novel treatment for chronic pain. |
| psilocybin | Decreases - wide range of effects against | chronic pain | Human | — | Not specified | Psilocybin as a novel treatment for chronic pain. |
| psilocybin | Increases - neuroplastic actions that improve | functional connectivity in brain regions involved in chronic pain | Human | — | Not specified | Psilocybin as a novel treatment for chronic pain. |
| Psilocybin | Decreases - offering significant pain relief | pain | Human | a patient with refractory symptoms | Not available | Refractory CRPS pain treated with psilocybin: A case report.cited 3× |